Compounds > tenofovir
Page last updated: 2024-08-24

tenofovir and dolutegravir

tenofovir has been researched along with dolutegravir in 121 studies

Research

Studies (121)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's48 (39.67)24.3611
2020's73 (60.33)2.80

Authors

AuthorsStudies
Fang, J; Jadhav, PR1
Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F1
Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY1
Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S1
Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G1
Del Prete, GQ; Geleziunas, R; Hattersley, J; Hesselgesser, J; Jones, GS; Keele, BF; Li, B; Lifson, JD; Macallister, R; Piatak, M; Smedley, J; Zheng, J1
Doll, M; Kleinberg, M; Kokh, D; Riedel, DJ1
Jones, R; Levy, JB; Milburn, J1
Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F1
Buscemi, L1
Destache, CJ; Mandal, S; Prathipati, PK1
Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N1
Albert, J; Blaxhult, A; Carlander, C; Eriksen, J; Flamholc, L; Gisslén, M; Josephson, F; Karlström, O; Navér, L; Sönnerborg, A; Svedhem, V; Yilmaz, A1
Benson, P; Brinson, C; Cheng, A; Crofoot, G; DeJesus, E; Dretler, R; Martin, H; Mills, A; Peloquin, J; Quirk, E; Sax, PE; Ward, D; Wei, X; White, K1
Carr, A; Foster, R; McAllister, JW; Mcnulty, A; Pierce, AB; Richardson, R; Towns, JM1
Boffito, M; Flexner, CW; Maartens, G1
Anderson, M; Bailey, B; Balba, G; Brooks, KM; Garrett, KL; George, JM; Kuriakose, SS; Lane, HC; Maldarelli, F; Pau, AK1
Aboud, M; Aylott, A; Belonosova, E; Buchanan, AM; Falcó, V; Hagins, DP; Man, CY; Orrell, C; Porteiro, N; Smith, KY; Vavro, C; Walmsley, S; Wynne, B1
Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D1
Antinori, A; Cheng, A; Custodio, J; DeJesus, E; Garner, W; Koenig, E; Montes, ML; Pozniak, A; Quirk, E; Reynes, J; Sax, PE; SenGupta, D; Slim, J; Stellbrink, HJ; White, K; Workowski, K1
Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G1
Shafer, RW1
Aboud, M; Angelis, K; Cupo, M; De Wet, J; Gartland, M; Kahl, LP; Lupo, S; McComsey, GA; Parks, D; Poggio, MC; Vandermeulen, K; Wynne, B1
Aboud, M; Angelis, K; Blair, EA; Brinson, C; Castelli, F; Gartland, M; Girard, PM; Hung, CC; Kahl, LP; Llibre, JM; Smith, K; Underwood, M; Vandermeulen, K; Wynne, B1
Andrews, E; Bay, C; De Paris, K; Dellon, ES; Gay, CL; Kashuba, AD; Madanick, RD; Nelson, JA; Prince, HA; Rosen, EP; Shaheen, NJ; Sykes, C; Weber, MD1
Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR1
Castagna, A; Lazzarin, A; Spagnuolo, V1
Casado, JL; Fontecha, M; Monsalvo, M; Rodriguez-Sagrado, MA; Rojo, AM1
Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D1
Calvez, V; Dabis, F; Danaviah, S; de Oliveira, T; Derache, A; Giandhari, J; Gupta, RK; Iwuji, CC; Marcelin, AG; Pillay, D1
Eberle, J; Kroidl, A1
Aboud, M; Antinori, A; Arribas, JR; Cahn, P; Clarke, AE; Currie, A; Fettiplace, A; Gartland, M; Girard, PM; Hung, CC; Madero, JS; Man, C; Ortiz, R; Pappa, K; Rockstroh, JK; Sievers, J; Smith, K; Tenorio, AR; Underwood, M; Wynne, B1
Baptiste, SL; Etya'ale, HM; Taro, TB1
Bagella, P; Baldin, G; Capetti, A; Ciccullo, A; Cossu, MV; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Rusconi, S; Sterrantino, G1
Heldwein, S; Jaeger, H; Noe, S; Page, M; Wolf, E1
Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E1
Antinori, A; Calcagno, A; Ceccherini-Silberstein, F; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Maggiolo, F; Marchetti, G; Mondi, A; Rusconi, S; Tavelli, A; Vichi, F1
Choi, J; Nikoomanesh, K; Uppal, J; Wang, S1
Hauser, KF; Ismaiel, OA; McRae, M; Mylott, WR; Patel, SH; Yuan, M1
Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y1
Barber, TJ1
Acosta, R; Albrecht, H; Arribas, JR; Brainard, D; Collins, SE; Creticos, C; Maggiolo, F; Martin, H; Martorell, CT; Sax, PE; Stellbrink, HJ; Stephens, JL; Wei, X1
Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M1
Katzenstein, D; Kouamou, V; Makadzange, AT; Manasa, J; McGregor, AM; Ndhlovu, CE1
Hauser, KF; Ismaiel, OA; McClay, JL; McRae, M; Mylott, WR; Paris, JJ; Patel, SH; Yuan, M1
Buch, S; Burkovetskaya, ME; Callen, S; Chivero, ET; Guo, ML; Periyasamy, P; Thangaraj, A; Tripathi, A1
Borghi, V; Di Giambenedetto, S; Francisci, D; Franzetti, M; Giacomelli, A; Lai, A; Lepore, L; Lombardi, F; Maggiolo, F; Magnani, G; Monno, L; Paolucci, S; Pecorari, M; Rusconi, S; Vicenti, I1
Saag, MS1
Kerkemeyer, KLS; Lai, FYX; Mar, A1
Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T1
Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B1
Lodi, VJC; Monteiro, JCMS; Pires, CAA; Rego, RM1
Aboud, M; Baril, JG; Bogner, J; Eron, J; Falcó, V; Gartland, M; Hung, CC; Koteff, J; Maggiolo, F; Man, CY; Mills, A; Pappa, KA; Sievers, J; Slim, J; Smith, KY; Tenorio, AR; Underwood, M; Urbaityte, R; Wynne, B1
Howe, Z; Huesgen, E; Moore, SE1
Ajibola, G; Batlang, O; Bennett, K; Davey, S; Diseko, M; Hughes, MD; Isaacson, A; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Moyo, S; Sakoi, M; Shapiro, R; Zash, R1
Abrams, EJ; Bartilol, K; Batuka, J; Gitonga, M; Imbuki, E; Kimani, M; Lahuerta, M; Odhiambo, J; Odhiambo, S; Sugandhi, N; Syowai, M; Vakil, S; Wamicwe, J1
Alagaratnam, J; Boffito, M; Bozzali, M; Cercignani, M; Mora-Peris, B; Nelson, M; Toniolo, S; Underwood, J; Vera, JH; Winston, A1
Hill, A; Venter, WDF1
Acosta, R; Arribas, JR; Brainard, DM; Brinson, C; Clarke, A; Collins, SE; DeJesus, E; Flamm, JA; Gupta, SK; Hagins, D; Huang, H; Maggiolo, F; Martin, H; Martorell, C; Orkin, C; Podzamczer, D; Sax, PE; Stellbrink, HJ; Stephens, JL; Thompson, MA; Wohl, D1
Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H1
Acosta, RK; Andreatta, K; Collins, S; Liu, H; Martin, H; Martin, R; Parvangada, A; White, KL; Willkom, M1
Alhassan, Y; Kambugu, A; Khoo, S; Lamorde, M; Malaba, T; Myer, L; Orrell, C; Reynolds, H; Taegtmeyer, M; Twimukye, A; Waitt, C1
Agrati, C; Antinori, A; Capobianchi, MR; Casetti, R; Castilletti, C; Cicalini, S; Cimini, E; Colavita, F; De Zottis, F; Gagliardini, R; Girardi, E; Ippolito, G; Maeurer, M; Matusali, G; Mazzotta, V; Mondi, A; Pinnetti, C; Puro, V; Schininà, V; Vaia, F; Vergori, A1
Barbini, B; Campbell, L; Gilleece, Y; Hamzah, L; Ibrahim, F; Kegg, S; Post, FA; Samarawickrama, A; Vincent, R; Waters, L1
Abrams, E; Akpomiemie, G; Arulappan, N; Chandiwana, N; Chersich, M; Clayden, P; Fairlie, L; Hill, A; Lalla-Edward, S; Maartens, G; Masenya, M; Mashabane, N; McCann, K; Moorhouse, M; Norris, S; Qavi, A; Serenata, C; Simmons, B; Sokhela, S; Venter, WDF; Vos, A1
Burkholder, GA; Collier, AC; Crane, HM; Curtis, L; Delaney, JAC; Eron, JJ; Geng, E; Harding, BN; Henegar, C; Kitahata, MM; Lindström, S; Mathews, WC; Mayer, KH; Moore, RD; Nance, RM; Rodriguez, B; Ruderman, SA; Saag, MS; Van Wyk, J; Vannappagari, V; Whitney, BM; Willig, AL; Wood, BR1
Ait-Khaled, M; Ajana, F; Jones, B; Nascimento, MC; Santos, J; Scholten, S; Smith, DE; Tenorio, AR; van Wyk, J; Wohlfeiler, M; Wright, J; Wynne, B1
Bradford, Y; Chandiwana, NC; Cindi, Z; Haas, DW; Maartens, G; Sinxadi, P; Sokhela, S; Venter, WDF1
Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L1
Bowen, AC; Campbell, AJ; Yeoh, DK1
Cassidy, T; Flowers, T; Gcwabe, Z; Goemaere, E; Goliath, R; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Sayed, K; Schutz, C; Simmons, B; van Zyl, G; Wiesner, L; Zhao, Y1
Marukutira, T; Wood, BR1
Asif, S; Baxevanidi, E; Chandiwana, N; Fairlie, L; Hill, A; Masenya, M; Serenata, C; Sokhela, S; Venter, WDF1
Asienzo, J; Ategeka, G; Balyegisawa, A; Castelnuovo, B; Hakim, J; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Mirembe, G; Mugerwa, H; Musaazi, J; Paton, NI; Siika, A; Tukamushabe, P; Walimbwa, S1
Armas, D; Fillgrove, KL; Fox-Bosetti, S; Friedman, E; Iwamoto, M; Matthews, RP; Rudd, DJ; Stoch, SA; Zhang, S1
Affram, Y; Benedetti, F; Bryant, J; Denaro, F; Heredia, A; Latinovic, OS; Munawwar, A; Ramadhani, HO; Reitz, M; Rikhtegaran-Tehrani, Z; Romerio, F; Sajadi, MM; Tagaya, Y; Weichseldorfer, M; Williams, SP; Zella, D1
Dodda, S; Gangarapu, K; Veerareddy, V1
Barbini, B; Campbell, L; Fox, J; Gilleece, Y; Ibrahim, F; Orkin, C; Post, FA; Samarawickrama, A; Tariq, S; Waters, L1
Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P1
Bowen, N; Inzaule, SC; Jordan, MR; Kiiru, JN; Kingwara, L; Momanyi, L; Ngugi, C; Nyanya, W; Oramisi, V1
Chen, P; Deng, L; Hong, Z; Li, C; Luo, X; Xia, J; Zheng, X; Zhou, L; Zhou, Y1
Barrail-Tran, A; Benzemrane, MS; Bourgeois, C; Gelé, T; Gouget, H; Labarthe, L; Lambotte, O; Le Calvez, P; Le Grand, R; Legrand, N1
Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B1
Siva, N1
Ake, JA; Bahemana, E; Chang, D; Crowell, TA; Dear, NF; Esber, AL; Iroezindu, M; Kibuuka, H; Maswai, J; Owuoth, J; Polyak, CS; Singoei, V1
Blanco, JR; Calzado Isbert, S; López Cortés, LF; Martínez-Sanz, J; Mena, Á; Moreno, E; Moreno, S; Muriel, A; Pineda, JA; Ron, R; Sánchez-Conde, M; Serrano-Villar, S1
Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S1
Amstutz, A; Belus, JM; Brown, JA; Glass, TR; Klimkait, T; Labhardt, ND; Mokhele, K; Muhairwe, J; Nsakala, BL; Rakuoane, I; Tschumi, N1
Abel, S; Ajana, F; Avettand-Fenoel, V; Bauer, R; Calin, R; Chéret, A; Goujard, C; Lacombe, K; Lascoux, C; Lopez, P; Meiffrédy, V; Meyer, L; Morlat, P; Reynes, J; Rouzioux, C1
Chang, HY; Chang, SF; Chang, SY; Chen, GJ; Chen, LY; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Sheng, WH; Su, YC; Sun, HY; Wu, PY1
Evans, D; Hans, L; Levin, L; Steegen, K; Technau, KG1
Alhassan, Y; Bokako, S; Burger, D; Byamugisha, J; Byrne, K; Chen, T; Chiong, J; Colbers, A; Hodel, EM; Hu, NC; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Mrubata, M; Myer, L; Nakatudde, I; Orrell, C; Read, J; Read, L; Reynolds, H; Seden, K; Stemmet, LA; Taegtmeyer, M; Theunissen, H; Twimukye, A; Waitt, C; Wang, D1
Abdi, B; Bitilinyu-Bangoh, JE; Calvez, V; Descamps, D; Jahn, A; Kalua, T; Lê, MP; Marcelin, AG; Nicholas, S; Ousley, J; Peytavin, G; Schramm, B; Storto, A; Szumilin, E; Temfack, E1
Katzenstein, D; Kouamou, V; Machekano, R; Manasa, J; Mapangisana, T; Maposhere, C; McCarty, K; Munyati, S; Mutsvangwa, J; Shamu, T1
Cattaneo, D; Cinausero, M; Fusi, M; Gervasoni, C; Londero, A; Tascini, C1
Cai, L; Guo, Z; He, S; Wang, Y; Wang, Z; Yan, D; Yang, X; Zheng, Y1
Alcantarini, C; Bono, V; Bonora, S; Calcagno, A; Cannizzo, ES; Cusato, J; D'Avolio, A; De Nicolò, A; De Vivo, E; Di Perri, G; Ferrara, M; Ianniello, A; Marchetti, G; Nozza, S; Salvador, E; Trentalange, A; Trunfio, M1
Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H1
Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF1
Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y1
Aristegui, I; Cahn, P; Cardozo, N; Cesar, C; Figueroa, MI; Fink, V; Frola, CE; Gun, A; Patterson, P; Radusky, PD; Sued, O; Zalazar, V1
Abba, A; Beloumou, GA; Billong, SC; Bouba, NP; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa Ndjeyep, SC; Eben-Moussi, E; Etame, NK; Fokam, J; Ka'e, AC; Kengni, AMN; Kouanfack, C; Meledie, AP; Molimbou, E; Mossiang, L; Ndjolo, A; Nka, AD; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Teto, G; Tommo Tchouaket, MC; Yagai, B; Zoung-Kanyi Bissek, AC1
Cassidy, T; Flowers, T; Goemaere, E; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Omar, Z; Sayed, K; Van Zyl, G; Zhao, Y1
Lunn, G1
Adede, RO; Ayieko, J; Balzer, LB; Garraza, LG; Havlir, DV; Hickey, MD; Ogachi, SM; Ojwando, H; Orori, G; Petersen, ML; Wafula, E1
Caldeira, DB; Camargo, M; de Lima, IB; Dias, D; Diaz, RS; Galinskas, J; Hunter, JR; Nassar, I; Schechter, M; Sucupira, MC1
Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y1
Hachey, D; Shiluama, R; Singu, BS; van Woerden, I1
Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L1
Ambe Chenwi, C; Billong, SC; Bouba, Y; Colizzi, V; Ebiama Lifanda, L; Efakika Gabisa, J; Fainguem, N; Flore Yimga, J; Fokam, J; Hadja, H; Halle, EG; Ka'e, AC; Kamgaing, N; Kembou, E; Kengni Ngueko, AM; Kesseng, D; Ketchaji, A; Mamgue Dzukam, FY; Moudourou, S; Nayang Mundo, RA; Ndiang Tetang, S; Ndjolo, A; Ndombo Koki, P; Ngoufack Jagni Semengue, E; Njom-Nlend, AE; Nka, AD; Nnomo Zam, MK; Pabo, W; Pamen, B; Perno, CF; Saounde Temgoua, E; Simo Kamgaing, R; Sosso, SM; Takou, D; Tangimpundu, C; Tommo Tchouaket, MC; Zoung-Kanyi Bissek, AC1
Abbasian, L; Alavian, G; Alinaghi, SAS; Ashtiani, MF; Hasannezhad, M; Khalili, H; Manshadi, SAD1
Ajeh, R; Beloumou, G; Bouba, NP; Cappelli, G; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa, S; Fokam, J; Kembou, E; Mbanya, D; Ndjolo, A; Perno, CF; Santoro, MM; Semengue, ENJ; Takou, D; Tala, V; Teto, G1
Collier, AC; Delle Fratte, R; Eguchi, M; Ho, RJY; Melvin, AJ; Perazzolo, S; Stephen, ZR; Xu, X1
Mhembere, T; Stranix-Chibanda, L1
Bansi-Matharu, L; Cambiano, V; Cowan, F; Ehrenkranz, P; Gilks, CF; Godfrey, C; Hargreaves, JR; Lundgren, JD; Phillips, AN; Revill, P; Rodger, A; Shahmanesh, M; Sibanda, E; Sikwese, K; Smith, J1
Butler, CC; Dorward, J; Drain, PK; Gandhi, M; Garrett, N; Govender, K; Hayward, G; Lessells, R; Moodley, P; Samsunder, N; Sookrajh, Y; Turner, P1
Buteaue, J; Dos Santos, G; Duval, N; Francois, K; Geffrard, H; Giron, A; Inzaule, SC; Jordan, MR; Journel, I; Pierre, E; Sued, O; Van Onacker, JD1
Kouamou, V; Manasa, J; Ndhlovu, CE; Washaya, T1
Ait-Khaled, M; Espinosa, N; Fernvik, E; Grove, R; Gulminetti, R; Hagins, D; Man, C; Sierra Madero, J; Sievers, J; Tsai, HC; van Wyk, J; Wynne, B; Zolopa, A1
Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B1

Reviews

8 review(s) available for tenofovir and dolutegravir

ArticleYear
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load

2014
Renal effects of novel antiretroviral drugs.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 03-01, Volume: 32, Issue:3

    Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir

2017
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
    AIDS research and therapy, 2016, Volume: 13, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome

2016
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
    Current opinion in HIV and AIDS, 2017, Volume: 12, Issue:4

    Topics: Adenine; Alanine; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Rifampin; Tenofovir

2017
Bictegravir.
    Current opinion in HIV and AIDS, 2018, Volume: 13, Issue:4

    Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Tenofovir

2018
Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
    Expert review of clinical pharmacology, 2018, Volume: 11, Issue:6

    Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine; Tenofovir

2018
Community and activists demand for tenofovir/emtricitabine or lamivudine/dolutegravir and routine viral load testing.
    Current opinion in HIV and AIDS, 2019, Volume: 14, Issue:1

    Topics: Anti-HIV Agents; Drug Monitoring; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Residence Characteristics; Tenofovir; Viral Load

2019
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir dis
    AIDS (London, England), 2021, 12-15, Volume: 35, Issue:Suppl 2

    Topics: Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Obesity; Oxazines; Piperazines; Pregnancy; Pregnancy Outcome; Pyridones; Tenofovir

2021

Trials

38 trial(s) available for tenofovir and dolutegravir

ArticleYear
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
    Journal of pharmacokinetics and pharmacodynamics, 2012, Volume: 39, Issue:4

    Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles

2012
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:11

    Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir

2013
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir

2016
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    The lancet. HIV, 2017, Volume: 4, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load; Young Adult

2017
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label
    The lancet. HIV, 2017, Volume: 4, Issue:12

    Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome

2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Lancet (London, England), 2017, Nov-04, Volume: 390, Issue:10107

    Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult

2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
    Lancet (London, England), 2017, Nov-04, Volume: 390, Issue:10107

    Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult

2017
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
    AIDS (London, England), 2018, 02-20, Volume: 32, Issue:4

    Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Oxazines; Pelvic Bones; Piperazines; Pyridones; Rilpivirine; Spine; Tenofovir; Treatment Outcome

2018
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
    Lancet (London, England), 2018, 03-03, Volume: 391, Issue:10123

    Topics: Adult; Aged; Anti-HIV Agents; Bone Density; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load

2018
Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.
    Antiviral therapy, 2018, Volume: 23, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colon, Transverse; DNA, Viral; Emtricitabine; Female; Gene Expression; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Ileum; Immunity, Innate; Lymphoid Tissue; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Receptors, Antigen, T-Cell, gamma-delta; Rectum; RNA, Viral; Tenofovir; Treatment Outcome

2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
    The lancet. HIV, 2018, Volume: 5, Issue:7

    Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult

2018
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
    The Journal of antimicrobial chemotherapy, 2019, 02-01, Volume: 74, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cytosine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; South Africa; Tenofovir; Viral Load; Young Adult

2019
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior
    Lancet (London, England), 2019, 01-12, Volume: 393, Issue:10167

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load

2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    The lancet. HIV, 2019, Volume: 6, Issue:6

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load

2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer
    The lancet. HIV, 2019, Volume: 6, Issue:6

    Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome

2019
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
    The New England journal of medicine, 2019, 08-29, Volume: 381, Issue:9

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain

2019
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 11-05, Volume: 71, Issue:8

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load

2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
    Journal of acquired immune deficiency syndromes (1999), 2020, 05-01, Volume: 84, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Young Adult

2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
    The lancet. HIV, 2020, Volume: 7, Issue:6

    Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult

2020
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Journal of acquired immune deficiency syndromes (1999), 2020, 11-01, Volume: 85, Issue:3

    Topics: Adenine; Amides; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Logistic Models; Multivariate Analysis; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir

2020
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
    HIV medicine, 2021, Volume: 22, Issue:2

    Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Kidney; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain

2021
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n
    The lancet. HIV, 2020, Volume: 7, Issue:10

    Topics: Adenine; Adolescent; Adult; Alanine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Weight; Cyclopropanes; Duration of Therapy; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load; Young Adult

2020
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
    Journal of acquired immune deficiency syndromes (1999), 2021, 06-01, Volume: 87, Issue:2

    Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Insulin Resistance; Lamivudine; Lipids; Metabolic Syndrome; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Weight Gain

2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
    Lancet (London, England), 2021, 04-03, Volume: 397, Issue:10281

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridones; Tenofovir; Ultrasonography, Prenatal

2021
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
    The New England journal of medicine, 2021, 07-22, Volume: 385, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Drug Resistance; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Young Adult; Zidovudine

2021
Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate.
    Clinical pharmacology in drug development, 2021, Volume: 10, Issue:12

    Topics: Adult; Anti-Retroviral Agents; Deoxyadenosines; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir

2021
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
    HIV medicine, 2022, Volume: 23, Issue:4

    Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Middle Aged; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir

2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-29, Volume: 75, Issue:6

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Oxazines; Piperazines; Pyridones; RNA; Tenofovir

2022
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
    The lancet. HIV, 2022, Volume: 9, Issue:6

    Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine

2022
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
    The Journal of antimicrobial chemotherapy, 2022, 08-25, Volume: 77, Issue:9

    Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA; Tenofovir; Viral Load

2022
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
    The lancet. HIV, 2022, Volume: 9, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Oxazines; Piperazines; Postpartum Period; Pregnancy; Pyridones; Tenofovir; Viral Load

2022
Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
    AIDS research and human retroviruses, 2022, Volume: 38, Issue:10

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Protease Inhibitors; Tenofovir; Viral Load; Young Adult; Zimbabwe

2022
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 04-17, Volume: 76, Issue:8

    Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir

2023
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 05-24, Volume: 76, Issue:10

    Topics: Adult; Anti-Retroviral Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; RNA; Tenofovir

2023
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
    PloS one, 2023, Volume: 18, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Argentina; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Transgender Persons

2023
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
    The lancet. HIV, 2023, Volume: 10, Issue:7

    Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Isoniazid; Lamivudine; Rifampin; RNA; South Africa; Tenofovir; Tuberculosis; Viral Load

2023
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 09-18, Volume: 77, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir

2023
Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2023, Volume: 31, Issue:2

    Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Pilot Projects; RNA; Tenofovir; Treatment Outcome

2023

Other Studies

75 other study(ies) available for tenofovir and dolutegravir

ArticleYear
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
    AIDS (London, England), 2015, Jan-14, Volume: 29, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load

2015
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:6

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Emtricitabine; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Male; Oxazines; Piperazines; Pregnancy; Pyridones; Ritonavir; Tenofovir

2015
Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:2

    Topics: Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; Macaca mulatta; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome; Viral Load

2016
Loss of Virologic Control and Severe Pneumocystis pneumonia in an HIV-Infected Patient Receiving Chemotherapy for Non-Small Cell Lung Cancer.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:1

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Non-Small-Cell Lung; Cisplatin; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lung Neoplasms; Middle Aged; Oxazines; Pemetrexed; Piperazines; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyridones; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load

2016
Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Aug-01, Volume: 73, Issue:15

    Topics: Adult; Antiretroviral Therapy, Highly Active; Dosage Forms; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tablets; Tenofovir; Viral Load

2016
Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
    Journal of pharmaceutical and biomedical analysis, 2016, Sep-10, Volume: 129

    Topics: Animals; Anti-Retroviral Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir

2016
Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
    Infectious diseases (London, England), 2017, Volume: 49, Issue:1

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Early Detection of Cancer; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sweden; Tenofovir

2017
Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    AIDS (London, England), 2017, 06-01, Volume: 31, Issue:9

    Topics: Anti-HIV Agents; Australia; Chemoprevention; Disease Transmission, Infectious; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Medication Adherence; Oxazines; Piperazines; Post-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir; Treatment Failure

2017
Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
    Pharmacotherapy, 2017, Volume: 37, Issue:8

    Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Jejunostomy; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir

2017
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
    Journal of acquired immune deficiency syndromes (1999), 2018, 01-01, Volume: 77, Issue:1

    Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome

2018
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
    The Journal of infectious diseases, 2017, 12-01, Volume: 216, Issue:suppl_9

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Lopinavir; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Tenofovir

2017
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:8

    Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult

2018
A two-drug regimen for antiretroviral therapy.
    Lancet (London, England), 2019, 01-12, Volume: 393, Issue:10167

    Topics: Adult; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir

2019
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ
    HIV medicine, 2019, Volume: 20, Issue:2

    Topics: Adult; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; RNA, Viral; Tenofovir; Viral Load

2019
Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
    International journal of STD & AIDS, 2019, Volume: 30, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Calcium; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Hypocalcemia; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prevalence; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome

2019
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
    BMC infectious diseases, 2019, Jan-17, Volume: 19, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load

2019
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
    Journal of the International AIDS Society, 2019, Volume: 22, Issue:1

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Italy; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome

2019
Progressive disseminated histoplasmosis with concomitant disseminated nontuberculous mycobacterial infection in a patient with AIDS from a nonendemic region (California).
    BMC pulmonary medicine, 2019, Feb-21, Volume: 19, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Azithromycin; Bacteremia; California; Emtricitabine; Ethambutol; Fungemia; Heterocyclic Compounds, 3-Ring; Histoplasmosis; Humans; Lung; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Oxazines; Piperazines; Pyridones; Rifabutin; Tenofovir; Tomography, X-Ray Computed

2019
Simultaneous determination of intracellular concentrations of tenofovir, emtricitabine, and dolutegravir in human brain microvascular endothelial cells using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
    Analytica chimica acta, 2019, May-16, Volume: 1056

    Topics: Analytic Sample Preparation Methods; Anti-HIV Agents; Brain; Cell Line; Chromatography, Liquid; Emtricitabine; Endothelial Cells; Heterocyclic Compounds, 3-Ring; Humans; Intracellular Space; Linear Models; Oxazines; Piperazines; Pyridones; Reproducibility of Results; Tandem Mass Spectrometry; Tenofovir

2019
Bictegravir and dolutegravir: head to head at 96 weeks.
    The lancet. HIV, 2019, Volume: 6, Issue:6

    Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir

2019
Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    AIDS (London, England), 2019, 09-01, Volume: 33, Issue:11

    Topics: Adolescent; Cross-Sectional Studies; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Failure; Viral Load; Young Adult; Zimbabwe

2019
Cell-type specific differences in antiretroviral penetration and the effects of HIV-1 Tat and morphine among primary human brain endothelial cells, astrocytes, pericytes, and microglia.
    Neuroscience letters, 2019, 11-01, Volume: 712

    Topics: Analgesics, Opioid; Anti-Retroviral Agents; Astrocytes; Brain; Cells, Cultured; Chromatography, Liquid; Emtricitabine; Endothelial Cells; Heterocyclic Compounds, 3-Ring; Humans; Microglia; Morphine; Oxazines; Pericytes; Piperazines; Pyridones; Tandem Mass Spectrometry; tat Gene Products, Human Immunodeficiency Virus; Tenofovir

2019
Antiretroviral-Mediated Microglial Activation Involves Dysregulated Autophagy and Lysosomal Dysfunction.
    Cells, 2019, 09-28, Volume: 8, Issue:10

    Topics: Animals; Anti-Retroviral Agents; Autophagosomes; Autophagy; Cathepsin D; Cell Membrane Permeability; Cells, Cultured; Down-Regulation; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression Regulation; Heterocyclic Compounds, 3-Ring; Humans; Lysosomes; Male; Microglia; Models, Biological; Oxazines; Piperazines; Pyridones; Rats; Tenofovir

2019
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.
    Antiviral research, 2019, Volume: 172

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Genes, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load

2019
HIV 101: fundamentals of antiretroviral therapy.
    Topics in antiviral medicine, 2019, Volume: 27, Issue:3

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load

2019
Kaposi's Sarcoma Occurring in HIV Infection Controlled on HAART.
    The American journal of medicine, 2020, Volume: 133, Issue:6

    Topics: Ankle; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Emtricitabine; Foot; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lymphedema; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sarcoma, Kaposi; Skin Neoplasms; Sustained Virologic Response; Tenofovir; Viral Load

2020
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Ritonavir; Tenofovir; Treatment Outcome

2020
Kaposi's sarcoma in a HIV-positive patient: an exuberant and widespread case report in the Amazon.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2020, Volume: 62

    Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Sarcoma, Kaposi; Skin Neoplasms; Tenofovir

2020
Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis.
    International journal of STD & AIDS, 2020, Volume: 31, Issue:3

    Topics: Adult; Alanine; Anti-HIV Agents; Deglutition Disorders; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Eosinophilic Esophagitis; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load

2020
Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Journal of acquired immune deficiency syndromes (1999), 2020, 07-01, Volume: 84, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A Inducers; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Mothers; Oxazines; Piperazines; Pregnancy; Pyridones; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Young Adult

2020
Monitoring the transition to new antiretroviral treatment regimens through an enhanced data system in Kenya.
    PloS one, 2020, Volume: 15, Issue:4

    Topics: Anti-HIV Agents; Data Systems; Database Management Systems; Drug Monitoring; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load

2020
Changes in functional connectivity in people with HIV switching antiretroviral therapy.
    Journal of neurovirology, 2020, Volume: 26, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asymptomatic Diseases; Benzoxazines; Cognitive Dysfunction; Connectome; Cyclopropanes; Drug Substitution; Emtricitabine; Executive Function; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxazines; Piperazines; Prospective Studies; Pyridones; Raltegravir Potassium; Rilpivirine; Tenofovir

2020
Weighing considerations with newer antiretrovirals.
    The lancet. HIV, 2020, Volume: 7, Issue:6

    Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir

2020
Cases of coronavirus disease-2019 in HIV-infected transgender women.
    AIDS (London, England), 2020, 07-15, Volume: 34, Issue:9

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons

2020
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
    BMC health services research, 2020, Aug-01, Volume: 20, Issue:1

    Topics: Adult; Female; Government Programs; Health Facilities; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pregnancy; Pyridones; Qualitative Research; South Africa; Tenofovir; Uganda

2020
COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.
    Journal of medical virology, 2021, Volume: 93, Issue:3

    Topics: Anti-Retroviral Agents; Antibodies, Neutralizing; Antibodies, Viral; CD4 Lymphocyte Count; Coinfection; COVID-19 Drug Treatment; Cytokines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Immunity, Humoral; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Risk; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Tenofovir; Transgender Persons

2021
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Journal of acquired immune deficiency syndromes (1999), 2021, 03-01, Volume: 86, Issue:3

    Topics: Adult; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain

2021
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens.
    Journal of acquired immune deficiency syndromes (1999), 2021, 07-01, Volume: 87, Issue:3

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Genome-Wide Association Study; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Polymorphism, Genetic; Prodrugs; Pyridones; South Africa; Tenofovir; Weight Gain

2021
Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
    The Pediatric infectious disease journal, 2021, 05-01, Volume: 40, Issue:5

    Topics: Adolescent; Alanine; Anti-Retroviral Agents; Body Mass Index; Child; Cohort Studies; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Weight Gain

2021
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
    AIDS (London, England), 2021, 07-15, Volume: 35, Issue:9

    Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; South Africa; Tenofovir; Viral Load

2021
Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settings.
    AIDS (London, England), 2021, 07-15, Volume: 35, Issue:9

    Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir

2021
Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice.
    Journal of translational medicine, 2021, 10-30, Volume: 19, Issue:1

    Topics: Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Mice; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load

2021
Development and validation of ultra performance liquid chromatography-tandem mass spectrometry method for the simultaneous estimation of dolutegravir, lamivudine and tenofovir in bulk and tablet dosage form.
    European journal of mass spectrometry (Chichester, England), 2021, Volume: 27, Issue:6

    Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Heterocyclic Compounds, 3-Ring; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets; Tandem Mass Spectrometry; Tenofovir

2021
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
    AIDS (London, England), 2022, 01-01, Volume: 36, Issue:1

    Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain

2022
Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya.
    AIDS (London, England), 2022, 03-15, Volume: 36, Issue:4

    Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kenya; Lamivudine; Oxazines; Peptide Hydrolases; Piperazines; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir

2022
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
    BMC infectious diseases, 2022, Jan-04, Volume: 22, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Tenofovir

2022
Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice.
    The Journal of antimicrobial chemotherapy, 2022, 03-31, Volume: 77, Issue:4

    Topics: Animals; Anti-HIV Agents; Chromatography, Liquid; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Tenofovir; Tissue Distribution

2022
Gilead and ViiV Healthcare reach settlement over HIV drug.
    Lancet (London, England), 2022, 02-12, Volume: 399, Issue:10325

    Topics: Alanine; Anti-HIV Agents; Drug Combinations; Drug Industry; Emtricitabine; Heterocyclic Compounds, 3-Ring; Intellectual Property; Oxazines; Patents as Topic; Piperazines; Pyridones; Tenofovir

2022
Weight gain during the dolutegravir transition in the African Cohort Study.
    Journal of the International AIDS Society, 2022, Volume: 25, Issue:4

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain

2022
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Adult; Amides; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Cohort Studies; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir

2022
Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
    HIV medicine, 2023, Volume: 24, Issue:2

    Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lesotho; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Prospective Studies; Self Report; Tenofovir

2023
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
    International journal of antimicrobial agents, 2022, Volume: 60, Issue:3

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load; Viremia

2022
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
    The Pediatric infectious disease journal, 2022, 10-01, Volume: 41, Issue:10

    Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine

2022
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    The lancet. HIV, 2022, Volume: 9, Issue:8

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Malawi; Oxazines; Piperazines; Prospective Studies; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load

2022
Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report.
    AIDS (London, England), 2022, 09-01, Volume: 36, Issue:11

    Topics: Androgen Receptor Antagonists; Benzamides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Nitriles; Oxazines; Phenylthiohydantoin; Piperazines; Prostatic Neoplasms; Pyridones; Receptors, Androgen; Tenofovir

2022
Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Observ
    Journal of acquired immune deficiency syndromes (1999), 2022, 10-01, Volume: 91, Issue:S1

    Topics: Adult; Creatinine; Cystatin C; Female; Glomerular Filtration Rate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir

2022
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:3

    Topics: Anti-HIV Agents; Darunavir; Emtricitabine; HIV Infections; Humans; Inflammation; Interleukin-6; Lipopolysaccharide Receptors; Lipopolysaccharides; Tenofovir

2023
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
    Medicine, 2022, Oct-21, Volume: 101, Issue:42

    Topics: Adult; Anti-HIV Agents; Benzoxazines; Creatinine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Prospective Studies; Pyridones; RNA; Tenofovir; Triglycerides

2022
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
    Viruses, 2022, 12-21, Volume: 15, Issue:1

    Topics: Adult; Anti-HIV Agents; Benzoxazines; Cameroon; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load

2022
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
    Journal of acquired immune deficiency syndromes (1999), 2023, 04-15, Volume: 92, Issue:5

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Viral Load; Viremia

2023
Preliminary Evaluation of Stability Data for Dolutegravir-Containing Triple Active Formulations Intended for PEPFAR. Degradation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide as the Limiting Factor.
    Journal of pharmaceutical sciences, 2023, Volume: 112, Issue:6

    Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Hygroscopic Agents; Tablets; Tenofovir

2023
Weight Change Following Switch to Dolutegravir for HIV Treatment in Rural Kenya During Country Roll-Out.
    Journal of acquired immune deficiency syndromes (1999), 2023, 06-01, Volume: 93, Issue:2

    Topics: Adult; Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Male; Oxazines; Prospective Studies; Pyridones; Retrospective Studies; Tenofovir; Weight Gain

2023
Real world use of dolutegravir two drug regimens: Erratum.
    AIDS (London, England), 2023, 05-01, Volume: 37, Issue:6

    Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Pyridones; Tenofovir

2023
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil.
    BMC infectious diseases, 2023, May-24, Volume: 23, Issue:1

    Topics: Anti-Retroviral Agents; Brazil; HIV Infections; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure

2023
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
    International journal of STD & AIDS, 2023, Volume: 34, Issue:12

    Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain

2023
Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
    Medicine, 2023, May-19, Volume: 102, Issue:20

    Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Lamivudine; Male; Pediatrics; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load

2023
Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens.
    Viruses, 2023, 08-02, Volume: 15, Issue:8

    Topics: Cameroon; HIV Seropositivity; HIV-1; Humans; Lamivudine; Tenofovir

2023
A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.
    AIDS (London, England), 2023, 11-15, Volume: 37, Issue:14

    Topics: Animals; Anti-HIV Agents; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Lamivudine; Leukocytes, Mononuclear; Oxazines; Pharmaceutical Preparations; Pyridones; Tenofovir

2023
Unrestricted access to tenofovir, lamivudine, and dolutegravir as pre-exposure or post-exposure prophylaxis in community settings.
    The Lancet. Global health, 2023, Volume: 11, Issue:10

    Topics: Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Post-Exposure Prophylaxis; Tenofovir

2023
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.
    The Lancet. Global health, 2023, Volume: 11, Issue:10

    Topics: Africa, Western; Cost-Benefit Analysis; Female; HIV Infections; Humans; Lamivudine; Male; Tenofovir

2023
Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy.
    Journal of the International AIDS Society, 2023, Volume: 26, Issue:9

    Topics: Adult; Benzoxazines; Chromatography, Liquid; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Point-of-Care Systems; Tandem Mass Spectrometry; Tenofovir; Viremia

2023
First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers.
    AIDS (London, England), 2023, 11-01, Volume: 37, Issue:13

    Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Lamivudine; Mothers; Oxazines; Pregnancy; Tenofovir

2023
Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.
    Viruses, 2023, 09-05, Volume: 15, Issue:9

    Topics: Adult; Humans; Lamivudine; Prevalence; Prospective Studies; Tenofovir; Zimbabwe

2023
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
    Journal of acquired immune deficiency syndromes (1999), 2023, 11-01, Volume: 94, Issue:3

    Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Tenofovir; Treatment Adherence and Compliance

2023
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
    The Journal of antimicrobial chemotherapy, 2023, Dec-01, Volume: 78, Issue:12

    Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir

2023